Skip to main content
Year archive

IMMUTEP LIMITED — 2023 filings

All 83 regulatory filings released by IMMUTEP LIMITED (IMM) in 2023, sourced directly from the official regulator.

83 Filings
2023 Period
2023 filings (83)
Filing Released Lang
Change of Registered Office Address 1 page 218.9KB
Regulatory Filings
2023-12-21 English
PEI provides constructive feedback for ph3 lung cancer trial 2 pages 185.4KB
Regulatory Filings
2023-12-20 English
Immutep receives A$2.6 million French R&D Tax Incentive 1
Capital/Financing Update
2023-12-06 English
Notification regarding unquoted securities - IMM 5 pages 26.5KB
Transaction in Own Shares
2023-11-22 English
Change of Director's Interest Notice - R Howard 3 pages 133.6KB
Director's Dealing
2023-11-22 English
Change of Director's Interest Notice - L Boyce 3 pages 137.3KB
Director's Dealing
2023-11-22 English
Proposed issue of securities - IMM 5 pages 27.6KB
Share Issue/Capital Change
2023-11-21 English
Immutep Announces Site Expansion for INSIGHT-003 Trial 2 pages 285.1KB
Regulatory Filings
2023-11-21 English
Immutep Completes Enrolment for TACTI-003 Phase IIb Trial 3 pages 311.3KB
Regulatory Filings
2023-11-08 English
Lead-in phase completed for ph2/3 trial in Breast Cancer 2 pages 292.7KB
Capital/Financing Update
2023-11-05 English
New Biomarker Data from TACTI-002 trial in 1st line NSCLC 3 pages 311.3KB
Capital/Financing Update
2023-11-02 English
Immutep to Participate in November Investor Events 1
Regulatory Filings
2023-11-01 English
Immutep Quarterly Activities Report and Appendix 4C 9 pages 697.9KB
Interim / Quarterly Report
2023-10-30 English
Immutep receives Australian R&D Tax Incentive 1 pag
Capital/Financing Update
2023-10-24 English
Annual Report filed on Form 20-F with SEC 145 pages 770.0KB
Annual Report
2023-10-24 English
Immutep reports promising data from INSIGHT-003 trial 3 pages 367.6KB
Regulatory Filings
2023-10-23 English
Immutep AGM 2023 - Chairman's Address 3 pages 243.2KB
AGM Information
2023-10-23 English
Immutep AGM 2023 - CEO's Presentation 34 pages 4.1MB
AGM Information
2023-10-23 English
Results of Meeting 2 pages 180.9KB
Declaration of Voting Results & Voting Rights Announcements
2023-10-23 English
Excellent Overall Survival in Non-Small Cell Lung Cancer 4 pages 379.7KB
Capital/Financing Update
2023-10-22 English
Webcast slides for new Efti clinical data in 1st line NSCLC 25 pages 4.8MB
Investor Presentation
2023-10-22 English
Immutep announces publication of ESMO 2023 abstracts 3 pages 330.2KB
Regulatory Filings
2023-10-15 English
Change of Director's Interest Notice - Pete Meyers 3 pages 134.9KB
Director's Dealing
2023-10-04 English
Immutep announces acceptance of abstract for SITC 2023 2 pages 251.6KB
Regulatory Filings
2023-10-02 English
Application for quotation of securities - IMM 6 pages 28.5KB
Share Issue/Capital Change
2023-10-02 English
Annual Report to shareholders 86 pages 1.3MB
Annual Report
2023-09-21 English
Appendix 4G and Corporate Governance Statement 38 pages 795.7KB
Regulatory Filings
2023-09-21 English
Notice of Annual General Meeting/Proxy Form 25 pages 647.4KB
AGM Information
2023-09-21 English
Commercial Scale Manufacturing of Efti for Clinical Trials 2 pages 290.5KB
Capital/Financing Update
2023-09-20 English
2023 AGM & Key Dates 1 page 206.7KB
AGM Information
2023-09-07 English
Immutep to Participate in September Investor Conferences 1
Investor Presentation
2023-09-05 English
Appendix 4E & 2023 Full Year Statutory Accounts 93 pages 3.8MB
Annual Report
2023-08-29 English
Immutep Investor Update 9 pages 751.9KB
Investor Presentation
2023-08-17 English
Immutep receives positive scientific advice from EMA 2 pages 202.7KB
Regulatory Filings
2023-07-31 English
Immutep Quarterly Activities Report and Appendix 4C 10 pages 1.1MB
Interim / Quarterly Report
2023-07-30 English
Efti clinical data to be presented at ESMO Congress 2023 2 pages 283.6KB
Investor Presentation
2023-07-30 English
1st Patient Dosed in Phase 2 Soft Tissue Sarcoma Trial 2 pages 237.1KB
Regulatory Filings
2023-07-27 English
Application for quotation of securities - IMM 6 pages 27.7KB
Capital/Financing Update
2023-06-28 English
Immutep completes underwritten retail entitlement offer 2 pages 237.5KB
Capital/Financing Update
2023-06-26 English
US patent granted for Efti with PD-1 pathway inhibitor 2 pages 225.3KB
Regulatory Filings
2023-06-26 English
Immutep granted US patent for IMP761 agonist LAG-3 antibody 2 pages 223.6KB
Regulatory Filings
2023-06-19 English
Change in substantial holding 6 pages 1.6MB
Major Shareholding Notification
2023-06-12 English
Change in substantial holding 5 pages 421.5KB
Major Shareholding Notification
2023-06-12 English
Becoming a substantial holder 3 pages 250.2KB
Major Shareholding Notification
2023-06-08 English
Application for quotation of securities - IMM 7 pages 30.3KB
Share Issue/Capital Change
2023-06-07 English
Cleansing Notice 1 page 256.2KB
Capital/Financing Update
2023-06-07 English
Immutep retail entitlement offer booklet 110 pages 7.2MB
Capital/Financing Update
2023-06-05 English
Immutep letter to ineligible shareholders 3 pages 298.5KB
Capital/Financing Update
2023-06-05 English
Positive final data in 2nd line head and neck cancer at ASCO 3 pages 317.1KB
Capital/Financing Update
2023-06-04 English
Immutep completes institutional pro-rata offer & placement 5 pages 259.5KB
Capital/Financing Update
2023-06-01 English
Change in substantial holding 6 pages 329.6KB
Major Shareholding Notification
2023-05-31 English
Trading Halt 2 pages 307.0KB
Capital/Financing Update
2023-05-30 English
A$80 million fully underwritten equity raising 7 pages 325.5KB
Capital/Financing Update
2023-05-30 English
Immutep Capital Raising Presentation 63 pages 5.5MB
Investor Presentation
2023-05-30 English
Proposed issue of securities - IMM 11 pages 45.2KB
Capital/Financing Update
2023-05-30 English
Cleansing Notice 1 page 250.0KB
Capital/Financing Update
2023-05-30 English
Charles River Laboratories to run IMP761 Toxicology Study 2 pages 233.6KB
Capital/Financing Update
2023-05-28 English
Publication of Abstracts for ASCO 2023 Annual Meeting 2 pages 268.9KB
Regulatory Filings
2023-05-25 English
1st patient dosed in AIPAC-003 ph2/3 breast cancer trial 2 pages 225.1KB
Regulatory Filings
2023-05-24 English
Promising New Data in 1st line NSCLC from INSIGHT-003 Trial 3 pages 251.1KB
Capital/Financing Update
2023-05-23 English
Excellent initial Overall Survival Benefit in 1st line NSCLC 3 pages 252.2KB
Capital/Financing Update
2023-05-16 English
FDA supportive of Efti registrational trial in lung cancer 2 pages 231.0KB
Regulatory Filings
2023-05-15 English
Change of Director's Interest Notice - R Howard 3 pages 243.3KB
Director's Dealing
2023-05-01 English
Approval to start Efti & Bavencio trial in urothelial cancer 2 pages 249.4KB
Capital/Financing Update
2023-04-30 English
Immutep to announce new TACTI-002 data at ASCO 2023 2 pages 267.9KB
Regulatory Filings
2023-04-26 English
Immutep Quarterly Activities Report and Appendix 4C 9 pages 467.8KB
Interim / Quarterly Report
2023-04-26 English
Immutep appoints Dr Florian Vogl as Chief Medical Officer 2 pages 172.0KB
Board/Management Information
2023-04-25 English
Response to ASX Aware Query 7 pages 929.5KB
Regulatory Filings
2023-04-17 English
Initiation of Phase 2 Trial for Efti in Soft Tissue Sarcoma 3 pages 252.6KB
Regulatory Filings
2023-04-16 English
Immutep Announces Changes to the Board 1 page 217.2
Board/Management Information
2023-04-10 English
Appendix 3X - Lis Boyce 2 pages 162.5KB
Director's Dealing
2023-04-10 English
Appendix 3Z - Lucy Turnbull 2 pages 200.6KB
Director's Dealing
2023-04-10 English
Notification of cessation of securities - IMM 4 pages 24.2KB
Share Issue/Capital Change
2023-04-10 English
Change in substantial holding 6 pages 1.6MB
Major Shareholding Notification
2023-03-30 English
Positive Final Data in 2nd Line Metastatic NSCLC Patients 3 pages 282.2KB
Regulatory Filings
2023-03-30 English
Expansion of INSIGHT-003 trial for Efti in 1st Line NSCLC 3 pages 264.7KB
Capital/Financing Update
2023-03-29 English
Abstract accepted for ESMO's European Lung Cancer Congress 2 pages 284.7KB
Investor Presentation
2023-03-22 English
Initiation of Ph 2/3 Trial for Metastatic Breast Cancer 3 pages 225.9KB
Capital/Financing Update
2023-03-13 English
Half Yearly Report and Accounts 31 pages 716.1KB
Regulatory Filings
2023-02-23 English
Enrolment Target Reached for INSIGHT-003 Trial in NSCLC 2 pages 269.9KB
Regulatory Filings
2023-02-05 English
Immutep Quarterly Activities Report and Appendix 4C 10 pages 445.9KB
Interim / Quarterly Report
2023-01-29 English
Notification of cessation of securities - IMM 4 pages 24.3KB
Share Issue/Capital Change
2023-01-05 English
TACTI-003 trial 50% enrolment milestone has been achieved 3 pages 253.7KB
Regulatory Filings
2023-01-03 English